1. Market Research
  2. > Pharmaceutical Market Trends
Johnson & Johnson Company Analysis, Pharma Intelligence

Johnson & Johnson Company Analysis, Pharma Intelligence

  • July 2020
  • 62 pages
  • ID: 5779809
  • Format: PDF
  • Pharma Intelligence

Summary

Table of Contents

PharmaVitae explores Johnson and Johnson’s prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
Overview – Johnson and Johnson’s growth will be driven by its pharmaceuticals segment.
Key themes – [1] Oncology will be a considerable growth driver for Johnson and Johnson, as Darzalex and Imbruvica exhibit robust growth at blockbuster levels [2] Growth from immunology products Stelara and Tremfya will counter increasing biosimilar headwinds to Remicade [3] Johnson and Johnson’s neuroscience portfolio will also drive growth, with the Invega franchise and recently launched Spravato, along with key pipeline asset ponesimod.

Model updates (30 July 2020)

Darzalex forecast adjusted higher due to continued strong growth and market share gains, driven by patient uptake across all lines of therapy.
Tremfya sales adjusted lower due to current sales trends.

Model updates (1 June 2020)

Erleada forecast refined due to JNJ disclosing historical sales.

Model updates (26 February 2020)

Remicade forecast adjusted lower due to additional biosimilar launches in the US and increased discounts and rebates
Simponi forecast adjusted lower in Rest of World due to competition
Stelara forecast adjusted higher due to strong uptake in Crohn’s disease
Tremfya forecast adjusted higher due to uptake in psoriasis
Prezista / Prezcobix / Rezolsta / Symtuza forecast adjusted higher due to consolidation of JNJ’s HIV portfolio under one product entry, bringing in line with how JNJ reports
Symtuza forecast removed due to above-mentioned consolidation
Invega Sustenna / Trinza forecast adjusted higher due to new patient starts and persistency
Darzalex forecast adjusted higher due to continued strong market growth and share gains in the US and Europe, driven by patient uptake in all lines of therapy
Imbruvica forecast adjusted higher due to increased patient uptake globally and higher market share, driven primarily by first-line chronic lymphocytic leukemia
Zytiga forecast adjusted higher due to stronger-than-expected performance of authorized generic in the US and strong sales and share growth in Europe
Velcade forecast adjusted lower due to generic competition
Xarelto forecast adjusted higher in the US due to volume and market growth
Invokana forecast adjusted lower due to market share losses and safety label update
JNJ-4528 forecast pulled forward due to earlier-than-expected US and European filings, and a Chinese approval decision expected in late 2020.

Model updates (15 October 2019)

Remicade sales adjusted higher internationally due to better-than-anticipated performance
Stelara sales adjusted higher due to continued share gains in Crohn’s disease
Tremfya sales adjusted higher due to strong uptake in psoriasis
Imbruvica sales adjusted higher due to increased patient uptake globally, higher market share, and growth across multiple indications, primarily in first-line chronic lymphocytic leukemia
Velcade sales adjusted lower due to higher initial impact of generic competition
Xarelto sales adjusted higher due to better-than-expected volume growth offsetting the increased reimbursement issues seen in the US
Tracleer sales adjusted lower due to higher impact of generics.

Model updates (18 July 2019)

Darzalex sales adjusted higher due to continued penetration and market share gains
Xarelto sales adjusted lower due to significant reimbursement issues in the US, notably the increase in the legislative rate for the donut hole from 50% to 70%, along with higher Medicare and donut hole utilization
Zytiga sales adjusted higher due to lower-than-anticipated generic impact in the US and recent approvals in Europe and Asia for metastatic high-risk castration-sensitive prostate cancer based on the Phase III LATITUDE study
Balversa forecast added
JNJ-4528 (BCMA CAR-T) forecast added
Ponesimod forecast added.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Injectable Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)

  • $ 4250
  • September 2020
  • 134 pages

The injectable drugs market is expected to register a CAGR of nearly 11.1% during the forecast period. With an upsurge in the number of chronic diseases like diabetes and cancer, the need for drug delivery ...

  • World
  • APAC
  • Pharmaceutical
  • Infectious Disease
  • Industry analysis
  • Drug Approval
  • Diabetes Prevalence

Ionis Pharmaceuticals $ 3000 July 2020

Global Pectin Industry $ 4950 July 2020


ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on